Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 333

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 333
---
 commissions. Neither we nor the Selling Shareholder
can presently estimate the amount of compensation that any agent will receive from any purchasers of our common stock sold by the Selling
Shareholder.

We know of no existing arrangements
between the Selling Shareholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of
our Depositary Shares offered by this prospectus.

We may from time to time file
with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part
to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to
disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Shareholder, including
the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the Selling Shareholder,
any compensation paid by the Selling Shareholder to any such brokers, dealers, underwriters or agents, and any other required information.

We will pay the expenses incident
to the registration under the Securities Act of the offer and sale of our Depositary Shares covered by this prospectus by the Selling
Shareholder. As consideration for its irrevocable commitment to purchase our Depositary Shares under the Purchase Agreement, we have agreed
to issue to the Selling Shareholder 2.5% of the Commitment Amount in Depositary Shares, with 1.75% of such shares paid up front and the
balance pro-rated with each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as the case may be. We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of the Company and in connection with the preparation, negotiation and execution of the Purchase Agreement. See “The Committed Equity Financing” for more information.

| 168 |

We also have agreed to indemnify
the Selling Shareholder and certain other persons against certain liabilities in connection with the offering of our Depositary Shares
offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities. The Selling Shareholder has agreed to indemnify us against liabilities under the Securities
Act that